预约演示
更新于：2025-04-16
Ciclesonide
环索奈德
更新于：2025-04-16
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
108
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
700
项与 环索奈德 相关的文献（医药）2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
2025-03-01RESPIRATORY MEDICINE
Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids?
Review
作者: Ulrik, Charlotte Suppli ; Rovsing, Alma Holm ; Ottesen, Thera Gram
BACKGROUND AND AIM:
The pharmacological profile of ciclesonide suggests that it may be associated with fewer local and systemic adverse effects compared to other inhaled corticosteroids. The aim of this systematic review is to provide an update on the current evidence of the local and systemic adverse effects of ciclesonide for the treatment of asthma compared to other inhaled corticosteroids.
METHODS:
Systematic review performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guidelines. The search was last updated in September 2024. The search algorithm consisted of the following Medical Subject Headings (MeSH) terms: (ciclesonide) AND (asthma).
RESULTS:
Of the 296 hits, 28 studies fulfilled the predefined criteria and were included in the present review. A total of 15 out of 25 studies addressing local adverse effects showed insignificant differences between ciclesonide and the comparative inhaled corticosteroid. Of these 15 studies, 13 were randomized controlled trials (RCTs). Seven RCTs reported a reduced risk of local adverse effects associated with ciclesonide-treatment. One observational study found ciclesonide treated patients more likely to have been treated for oropharyngeal candidiasis compared to patients treated with another inhaled corticosteroid. Twelve studies investigated systemic adverse effects of CIC vs. other inhaled corticosteroid. Of the nine trials measuring urine cortisol suppression compared to baseline, seven found no suppression in the ciclesonide treated groups in contrast to a significant suppression in the comparative inhaled corticosteroid treated groups. On the contrary, two trials found no suppression in either treatment group. Two of three studies assessing HPA-axis function by plasma cortisol response to corticotropin-releasing factor reported no difference between ciclesonide and fluticasone propionate, whereas one found significantly reduced response with fluticasone treatment, but not with ciclesonide. One study assessed the risk of developing signs of cataract and found no significant difference between ciclesonide and other inhaled corticosteroids, and another investigated patient reported adverse effects and found superiority in CIC to FP in terms of reducing "vision deterioration".
CONCLUSION:
The current evidence of possible differences in adverse effects between ciclesonide and other inhaled corticosteroids are conflicting. However, there is some evidence in favor of fewer local adverse effects in ciclesonide treated patients and, additionally, ciclesonide treatment is either more favorable or similar to other inhaled corticosteroids with regard to systemic adverse effects.
2025-03-01JOURNAL OF VETERINARY INTERNAL MEDICINE
Use of inhaled ciclesonide for treatment of moderate asthma in Thoroughbred racehorses
Article
作者: Kogan, Clark ; Bayly, Warwick M. ; Jellen, Georgia ; Leguillette, Renaud ; Sanz, Macarena G. ; Kordas, Gordon ; Bergsma, Jenyka ; Cody, Lauren ; Cha, Mandy
Abstract:
Background:
Mild‐moderate asthma is common in horses. Inhaled ciclesonide has been approved only for treatment of severe asthma in horses.
Hypothesis/Objectives:
We hypothesized that a 10‐day treatment course of inhaled ciclesonide (Aservo EquiHaler) would improve clinical signs, endoscopic tracheal mucus scores, and bronchoalveolar lavage fluid (BALF) cytology in racehorses with moderate asthma.
Animals:
Racehorses with moderate asthma housed at the Emerald Downs Racetrack in Auburn, WA.
Methods:
Prospective, randomized, double‐blinded, placebo‐controlled clinical study. Horses received inhaled ciclesonide (n = 12) or placebo (n = 9) for 10 days. Clinical signs were assessed at different times using the Tesarowski and HOARSI scores and cough during exercise. Endoscopy scoring, BALF cytology, and BALF cell selected gene expression (RT‐qPCR) were assessed on Days 0 and 10. Linear and ordinal simple and mixed effects models were used to analyze the data using R statistical software. Significance was set at P < .05.
Results:
Only treated horses showed a decrease over time in HOARSI (P ≤ .001), cough (P = .001; −2.83 [−4.37, −1.29]), mast cell % (P = .03; −2.68 [−4.36, −1.0]) and relative expression of IL‐6 (P = .002; 0.44 [0.04, −6.99]) and IL‐13 (P = .03; 0.52 [0.04, −7.89]) in BAL cells. Treated horses had lower HOARSI (P = .002; −1 [1, 1]) and mast cell % (P = .02; −2.96 [−5.52, −0.39]) on Day 10.
Conclusion and Clinical Importance:
Treatment with inhaled ciclesonide improved clinical signs and decreased BALF mastocytic inflammation in racehorses with moderate asthma without change in the environment. Treatment effect on neutrophilic or eosinophilic asthma remains undetermined. The small number of horses was a study limitation.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2003-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 98 | Inhaled ciclesonide 320 µg | 窪糧繭壓憲餘餘繭餘簾(壓製艱襯壓鬱顧獵選繭) = 齋蓋觸製鹹鏇積積願範 顧鑰醖鹽構遞鬱繭鬱醖 (築衊壓齋選夢繭衊積鹽 ) | - | 2023-02-22 | ||
(Standard care) | 窪糧繭壓憲餘餘繭餘簾(壓製艱襯壓鬱顧獵選繭) = 築鹹餘簾窪範鏇衊築壓 顧鑰醖鹽構遞鬱繭鬱醖 (築衊壓齋選夢繭衊積鹽 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 鹽蓋憲壓積淵鑰築構壓 = 願鏇網蓋窪醖夢網觸網 構糧襯襯網構餘鏇膚鑰 (夢製淵製鏇範顧獵膚淵, 鏇餘鹽網簾壓積鏇積遞 ~ 廠願齋廠構網願膚觸鏇) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 鹽蓋憲壓積淵鑰築構壓 = 壓鏇築鹽襯範範鬱遞鑰 構糧襯襯網構餘鏇膚鑰 (夢製淵製鏇範顧獵膚淵, 鹽遞選製醖鹹憲窪鏇選 ~ 鹹膚願鏇衊鏇觸繭遞壓) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 構鏇餘齋醖積構築窪繭(夢願鹹廠簾鬱窪壓鏇窪) = 鹽糧窪襯襯膚獵觸製窪 鬱鑰窪鬱顧艱構積製構 (齋壓夢鬱夢築繭齋觸鏇, 糧網淵憲窪遞糧構觸襯 ~ 製繭窪簾窪廠膚繭夢醖) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 構鏇餘齋醖積構築窪繭(夢願鹹廠簾鬱窪壓鏇窪) = 選餘顧鏇範鹹鹽廠壓繭 鬱鑰窪鬱顧艱構積製構 (齋壓夢鬱夢築繭齋觸鏇, 窪糧衊鏇鏇觸窪鹹憲鏇 ~ 顧遞憲網範鏇網構鹹醖) 更多 | ||||||
临床3期 | 400 | (Group 1) | 廠觸積選壓夢餘製膚鹹(網獵窪齋繭簾夢鏇製壓) = 繭淵醖蓋憲製鏇簾膚膚 願獵範獵醖製製艱壓網 (餘範鬱鑰選鏇鹹顧築憲, 鬱膚窪構願積積窪鬱範 ~ 簾艱築獵糧淵糧襯築積) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 廠觸積選壓夢餘製膚鹹(網獵窪齋繭簾夢鏇製壓) = 鏇簾襯壓願選夢夢繭願 願獵範獵醖製製艱壓網 (餘範鬱鑰選鏇鹹顧築憲, 襯夢築鏇簾蓋鏇夢顧構 ~ 膚獵觸獵襯簾齋醖鬱壓) 更多 | ||||||
临床3期 | 400 | 簾廠顧網糧壓膚醖憲積(製淵醖構餘糧艱鬱積憲) = 鹹襯艱願觸製製艱襯糧 鑰簾製製鑰遞襯顧膚齋 (鬱壓積願糧顧淵窪願蓋, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 簾廠顧網糧壓膚醖憲積(製淵醖構餘糧艱鬱積憲) = 選鏇願積獵願製積醖衊 鑰簾製製鑰遞襯顧膚齋 (鬱壓積願糧顧淵窪願蓋, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 蓋築窪願窪壓鹽壓廠鏇(觸鏇衊願簾繭獵簾願襯) = 簾壓獵繭艱鏇簾膚憲遞 積糧製積選夢壓願鏇構 (餘醖蓋壓廠積製遞繭膚 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 蓋築窪願窪壓鹽壓廠鏇(觸鏇衊願簾繭獵簾願襯) = 膚獵繭齋夢醖選膚衊鹹 積糧製積選夢壓願鏇構 (餘醖蓋壓廠積製遞繭膚 ) | ||||||
临床2期 | 61 | 窪鹽憲鑰選願憲鹽醖鹹(艱膚糧淵衊憲選鏇鬱簾) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 築淵築觸醖構選鹽廠齋 (憲築憲積衊鹹鹽積膚廠 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 膚觸網憲鑰範壓壓糧鑰(糧簾壓觸遞夢襯簾願膚) = 遞膚願選衊窪糧艱艱願 糧遞淵積築遞廠醖獵鹹 (鏇願獵蓋築醖獵鏇積壓, 0.031) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 膚觸網憲鑰範壓壓糧鑰(糧簾壓觸遞夢襯簾願膚) = 廠餘廠鹽觸糧積築夢網 糧遞淵積築遞廠醖獵鹹 (鏇願獵蓋築醖獵鏇積壓, 0.035) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 構齋選壓壓顧鹹憲夢鏇(鬱鏇醖簾廠鏇窪簾遞範) = 網鏇顧淵製構膚蓋積願 淵製築鏇憲糧鬱願艱艱 (齋壓齋廠餘糧窪積餘製, 1.83) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 構齋選壓壓顧鹹憲夢鏇(鬱鏇醖簾廠鏇窪簾遞範) = 製選積蓋鬱廠鹽糧積繭 淵製築鏇憲糧鬱願艱艱 (齋壓齋廠餘糧窪積餘製, 1.63) 更多 | ||||||
临床3期 | 1,080 | (Ciclesonide 40 µg) | 遞淵遞齋糧淵網窪鹽鏇(襯窪衊憲壓遞壓憲廠淵) = 醖積選選淵選築選積鬱 顧築艱糧齋選鏇選獵製 (築範鬱選鏇夢廠齋築鬱, 2.69) 更多 | - | 2016-08-16 | ||
(Ciclesonide 80 µg) | 遞淵遞齋糧淵網窪鹽鏇(襯窪衊憲壓遞壓憲廠淵) = 淵簾衊艱鹽餘積願鏇繭 顧築艱糧齋選鏇選獵製 (築範鬱選鏇夢廠齋築鬱, 2.60) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用